The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients
Blanda will be responsible for overseeing Evonik’s amino acids and functional feed additives business and the expansion of its precision livestock farming approach
Aimed at improving patient outcomes and increasing connectivity for more efficient monitoring In hospitals and homes
iNCOVACC was developed in partnership with Washington University St. Louis, which had designed and developed the recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy
NCDC branches in States/UTs will provide a boost to Public Health Infrastructurewith prompt surveillance, rapid detection and timely monitoring of diseases enabling Early Interventions
New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease
Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases.
CHMP recommendation based on safety, tolerability, and immunogenicity data from a Phase 2/3 trial of the Omicron BA.1-adapted bivalent vaccine
Phase 2 study to assess efficacy and safety of once daily linperlisib in patients with advanced peripheral T/NK cell lymphoma
The acquisition reaffirms Infosys’ commitment to help global life sciences companies
Subscribe To Our Newsletter & Stay Updated
